Society of Diabetic Nephropathy Prevention Journal of Nephropathology 2251-8363 15 1 2026 01 01 Administration of sodium-glucose cotransporter-2 inhibitors in IgA nephropathy; a new strategy in the management? e21429 e21429 10.34172/jnp.2023.21429 EN Anastasia Dieti https://orcid.org/0000-0002-8354-3662 Yeganeh Ragati Haghi https://orcid.org/0000-0001-6044-2677 Majid Forootan https://orcid.org/0000-0002-3691-2365 Journal Article 10.34172/jnp.2023.21429 2022 12 12 2023 02 01 Some of the several effects of sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including their metabolic, anti-inflammatory and hemodynamic properties, along with other kidney protective values, have directed clinicians to give these drugs in IgA-nephropathy (IgAN). According to recent studies regarding the beneficial effects of SGLT-2i on IgAN, it is clear that clinicians are changing their approach towards kidney transplantation when it comes to aggressive immunosuppression. This mini-review aims towards the evaluation of the protective efficacy of SGLT-2i in IgA-nephropathy.